On April 10, 2026, CMS released a proposed rule that extends prior authorization reform to drugs billed under the medical benefit — the first time federal policy has required electronic prior authorization for provider-administered therapies reimbursed under Medicare Part B. Medicare Advantage plans made 52.8 million prior authorization determinations in 2024, denying 4.1 million requests — a 7.7% denial rate that has pushed prior authorization management to the top of every specialty practice’s revenue cycle agenda. For orthopedics, pain management, and ASCs where physician-administered injectables, implants, and high-cost biologics are central to patient care, this rule adds new timelines, new transparency requirements, and new compliance obligations beginning October 1, 2027. The public comment period is open through June 15, 2026.
1. Revenue Cycle Impact: The Expansion to Drug Prior Authorization Under the Medical Benefit
CMS is extending its interoperability and prior authorization framework to cover drugs billed under the medical benefit — including provider-administered therapies under Medicare Part B. Previously, electronic prior authorization mandates applied only to procedures and devices. Under the new rule, payers would be required to incorporate drug coverage and documentation requirements into Prior Authorization APIs, allowing providers to determine requirements, submit requests, and receive decisions electronically within their EHR systems. For practices billing injectables, biologics, or infusion therapies, this closes a critical gap where manual, paper-based workflows remain common and denial rates are disproportionately high. The electronic framework must be operational for impacted payers by October 1, 2027 — a timeline that requires action now, not later.
2. Revenue Cycle Impact: Decision Timelines Get Dramatically Shorter
One of the most operationally significant changes in this proposed rule is the compression of payer response timelines for drug prior authorization decisions. For Medicaid and CHIP fee-for-service programs, CMS proposes a 24-hour standard turnaround for covered outpatient drugs. For Qualified Health Plans on the federally facilitated exchanges, the rule sets 72 hours for standard requests and 24 hours for expedited requests. This follows CMS’s September 2025 reform, which already cut the standard prior authorization decision window from 14 days to 7 calendar days for procedures. Practices that built their authorization follow-up cadences around legacy payer timelines will need to redesign workflows, tracking systems, and escalation
3. Revenue Cycle Impact: Mandatory Denial Explanations Change the Appeals Landscape
Beginning October 1, 2027, payers will be required to provide a specific reason for every drug prior authorization denial — not a denial code, not a generic explanation. For orthopedics and pain management practices that receive high volumes of medical-necessity denials for injectables and implants, specific denial reasons create a clearer, more defensible appeals pathway. CMS also introduced new public reporting requirements in March 2026, requiring insurers to disclose approval and denial metrics publicly for the first time — adding external accountability to payer decisions that previously occurred without visibility. Together, mandatory denial explanations and public transparency metrics shift the power dynamic in prior authorization appeals, giving practices documented grounds to challenge denials and the ability to compare their experience against published payer benchmarks.
4. Revenue Cycle Impact: Specialty Procedures Already Under Prior Authorization Scrutiny Get a Second Layer
The prior authorization pressure on specialty practices is not new, but this rule formalizes new infrastructure payers must use to apply it. CMS’s Wasteful and Inappropriate Service Reduction model already targets epidural steroid injections, knee arthroscopy, cervical fusion, nerve stimulator implants, and percutaneous vertebral augmentation for prior authorization review in select states. Adding drug prior authorization requirements to the same electronic framework means that any case involving a flagged procedure and an associated physician-administered drug — a common billing scenario in pain management, orthopedics, and anesthesia — now carries a two-layer authorization burden. Practices that lack coordinated workflows across procedure and drug authorizations are at elevated risk of both denial and delayed reimbursement on their highest-volume cases.
What This Means for Specialty Practices
Orthopedics, pain management, anesthesia, and ASC-based practices that rely on physician-administered drugs — injectables, biologics, and infusion therapies billed under the medical benefit — face real operational change under this proposed rule. Practices managing prior authorization manually today will absorb the highest compliance burden when electronic mandates take effect October 1, 2027. The 7.7% MA denial rate in 2024 — representing 4.1 million denied requests — reflects a system already strained by authorization complexity; adding a drug layer demands a proactive response, not a reactive one. According to industry data, practices that restructure authorization workflows in advance of rule finalization can reduce prior authorization denials by 40% or more. The comment period closes June 15, 2026, giving specialty practice leaders a final window to weigh in on implementation timelines that will directly shape their revenue cycle operations.
How Cosentus Helps Specialty Practices Protect Revenue
With 25 years of specialty-specific revenue cycle expertise and an R+A approach — real human experts working with artificial intelligence — Cosentus helps orthopedic, pain management, anesthesia, and ASC-based practices stay ahead of payer policy changes before they become revenue problems. Cosentus clients have achieved revenue and collections growth of up to 30% through a proactive RCM strategy that treats payer policy as part of the financial plan.
Managing prior authorization workflows end to end — procedures and physician-administered drugs — including submission, tracking, follow-up, and appeals.
Monitoring CMS and payer policy changes by specialty so your billing team is never responding to a rule that changed months ago.
Building specific denial reason documentation into appeals workflows so every prior authorization denial becomes a defensible, timely challenge.
Tracking your practice’s prior authorization approval rate against the 90%+ first-pass benchmark CMS targets, and closing the gap systematically.
Supporting practices in preparing for electronic prior authorization mandates so workflow transitions are planned well before the October 2027 implementation date.
Providing full revenue cycle visibility — payer by payer, procedure by procedure — so prior authorization risk is identified before it becomes a denial.
